Elevai Labs INC

PMGC Holdings Inc. announces the merger of its wholly owned subsidiaries, AGA Precision Systems LLC into A&B Aerospace, Inc., effective July 2, 2026.

PMGC Holdings Inc. subsidiary NorthStrive Defense Tech LLC has secured an exclusive worldwide license for aerospace and defense technologies covered by U.S. Patent No. 12,291,334.

NorthStrive Biosciences, a subsidiary of PMGC Holdings, announced positive Phase III results from its AI-driven drug discovery program with Yuva Biosciences, identifying four small-molecule candidates that increased ANT1 protein expression in human skeletal muscle cells.

PMGC Holdings Inc. shareholders approved a staggered board structure and re-elected five directors at the 2026 Annual Meeting.

PMGC Holdings' subsidiary NorthStrive Defense Tech has entered into an exclusive global licensing and research agreement with Florida State University for advanced aerospace and defense technology.

PMGC Holdings Inc. has acquired A&B Aerospace, Inc., a precision machining and aerospace manufacturing company, as part of its roll-up strategy.

PMGC Holdings Inc. reports significant revenue growth in Q3 2025 driven by recent acquisitions in IT packaging and precision engineering, despite an increased net loss and ongoing going concern doubts.

PMGC Holdings Inc. reports a net loss of $2.17 million for the first six months of 2025, following a strategic pivot from skincare to a diversified holding company with new acquisitions and significant capital raises.

PMGC Holdings Inc. announces its Q1 2025 financial results, highlighting a strategic shift towards diversified investments following the sale of its skincare business.

Elevai Labs Inc. saw a significant increase in revenue and gross profit in the third quarter of 2024, alongside strategic changes in management and operations.

Elevai Labs Inc. saw a significant increase in revenue during the second quarter of 2024, but also experienced substantial losses and challenges to its financial stability.

Elevai Labs Inc. saw a significant increase in revenue during the first quarter of 2024, but also experienced a substantial rise in operating expenses, leading to a net loss.

PMGC Holdings reported $0.59M in first-year operating revenue and a $7.75M net loss, executed dilutive financings backed by pledged subsidiaries, and plans to advance lead biotech asset EL-22 toward a U.S. IND in 2026.

PMGC Holdings Inc. divests its skincare business to concentrate on biotechnology assets, reporting a net loss of $6.25 million for fiscal year 2024.

Elevai Labs Inc. reports increased revenue and outlines strategic growth plans in its annual 10-K filing, while also acknowledging ongoing financial challenges.

PMGC Holdings Inc. CEO Graydon Bensler, through his wholly-owned entity GB Capital Ltd., has acquired 450,277 stock options.

PMGC Holdings Inc. director Jeffrey Parry was granted 75,046 stock options as compensation for his services.

Director George Kovalyov was granted 75,046 non-statutory stock options in PMGC Holdings Inc. as compensation for board services.

Director Juliana Daley was granted 75,046 non-statutory stock options in PMGC Holdings Inc. as compensation for her services.

Director Braeden Lichti was granted 450,277 stock options in PMGC Holdings Inc. as compensation for services rendered.

Graydon Bensler, CEO and CFO of PMGC Holdings Inc., reports acquisition of 3,036,437 shares of Series B Preferred Stock as a signing bonus.

PMGC Holdings Inc. announced its 2025 Annual Meeting agenda, revealing a combined 1:4,900 reverse stock split, a new $20 million dilutive equity line of credit, and ongoing related-party consulting agreements.

PMGC Holdings Inc. has secured an equity line of credit for up to $20 million, approved by majority shareholders, which will result in significant dilution for existing common stockholders.

PMGC Holdings Inc. adopted a new 2025 Equity Incentive Plan and significantly increased its authorized capital stock to 2.5 billion shares, approved by majority shareholders.

PMGC Holdings is holding a special meeting on March 26, 2025, to vote on proposals including increasing authorized common stock, implementing a staggered board, and approving bonus issuances of preferred stock to executives.

Elevai Labs Inc. is re-domesticating from Delaware to Nevada, becoming PMGC Holdings Inc., to eliminate Delaware franchise tax obligations.

Elevai Labs Inc. has increased its authorized shares to 2.5 billion through a written consent of majority shareholders, aiming for greater flexibility in future corporate actions.

PMGC Holdings Inc. filed an S-1/A registration statement for the resale of up to 5,000,000 shares of common stock by selling security holders, while detailing recent acquisitions and an equity line of credit.

PMGC Holdings Inc. filed an S-1/A detailing its transformation into a diversified holding company with a focus on biotechnology and manufacturing acquisitions, alongside significant capital raising activities.

PMGC Holdings Inc. filed an S-1 registration statement for the resale of up to 5 million common shares by Streeterville Capital, LLC, following a new $20 million equity line of credit and recent strategic acquisitions.

PMGC Holdings Inc. filed an S-1/A, outlining recent capital raises, strategic acquisitions in manufacturing and biotech, and a continued focus on its diversified portfolio despite ongoing financial losses.

PMGC Holdings Inc. filed an S-1 registration statement for the resale of up to 236,543 common shares underlying warrants, seeking to raise approximately $1.56 million from warrant exercises while grappling with significant net losses and going concern doubts.

PMGC Holdings Inc. has filed an amendment to its Form S-1 registration statement to register the resale of up to 559,261 shares of common stock underlying warrants issued to selling shareholders.

PMGC Holdings Inc. has filed an amendment to its Schedule 13D, detailing beneficial ownership changes and option grants to Northstrive Companies Inc.

Graydon Bensler and GB Capital Ltd. jointly file Schedule 13D, reporting a 7.40% stake in PMGC Holdings Inc. through stock and options.

PMGC Holdings Inc. CEO Graydon Bensler has disclosed a 47.64% beneficial ownership of the company's Series B Preferred Stock, acquired as a signing bonus through his wholly-owned entity, GB Capital Ltd.

Braeden Lichti, CEO of PMGC Holdings Inc., has acquired a 52.35% beneficial ownership stake in the company's Series B Preferred Stock, granted as a signing bonus through a consulting agreement.

Braeden Lichti, Chairman of PMGC Holdings Inc., has reported his beneficial ownership in the company has decreased to 0.19% due to the issuance of additional shares by the issuer, triggering an amended Schedule 13D filing.

Streeterville Capital LLC, along with affiliated entities, has disclosed a beneficial ownership of 453,920 shares, representing 9.99% of PMGC Holdings Inc.'s common stock, subject to a contractual ownership cap.

L1 Capital Global Opportunities Master Fund, Ltd. has significantly reduced its beneficial ownership in PMGC Holdings Inc. to 1.0% of outstanding common stock.

Streeterville Capital LLC, along with Streeterville Management LLC and John M. Fife, reported beneficial ownership of 9.99% of PMGC Holdings Inc.'s common stock.

Streeterville Capital LLC, along with its management entities, reported a passive beneficial ownership of 9.9% in PMGC Holdings Inc., totaling 90,452 shares.

L1 Capital Global Opportunities Master Fund, Ltd. increased its beneficial ownership in PMGC Holdings Inc. to 6.53% through a warrant exercise and received new warrants.

S.H.N. Financial Investments Ltd. has reported a complete divestment of its beneficial ownership in PMGC Holdings Inc., reducing its stake from 387,754 shares to zero percent.